Luis Vallejo-Castillo

Dr. Luis Vallejo-Castillo

Immunology, Instituto Politécnico Nacional, Mexico City, Ciudad de México, Mexico
orcid
Immunology Department, National Polytechnic Institute. Mexic...

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VCVíctor R. Campos-García
Víctor R. Campos-García
DHDaniel Herrera-Fernández
Daniel Herrera-Fernández
CGCarlos E. Espinosa-De la Garza
Carlos E. Espinosa-De la Garza
GGGerman González
German González
Luis Vallejo-CastilloLuis Vallejo-Castillo
Luis Vallejo-Castillo
LFLuis F. Flores-Ortiz
Luis F. Flores-Ortiz
Glatiramer Acetate (GA) is an immunomodulatory medicine approved for the treatment of multiple sclerosis, whose mechanisms of action are yet to be fully elucidated. GA is comprised of a complex mixture of polypeptides with different amino acid sequences and structures. The lack of sensible information about physicochemical characteristics of GA has contributed to its comprehensiveness complexity. Consequently, an unambiguous determination of distinctive attributes that define GA is of highest relevance towards dissecting its identity. Herein we conducted a study of characteristic GA heterogeneities throughout its manufacturing process (process signatures), revealing a strong impact of critical process parameters (CPPs) on the reactivity of amino acid precursors; reaction initiation and polymerization velocities; and peptide solubility, susceptibility to hydrolysis, and size-exclusion properties. Further, distinctive GA heterogeneities were correlated to defined immunological and toxicological profiles, revealing that GA possesses a unique repertoire of active constituents (epitopes) responsible of its immunological responses, whose modification lead to altered profiles. This novel approach established CPPs influence on intact GA peptide mixture, whose physicochemical identity cannot longer rely on reduced properties (based on complete or partial GA degradation), providing advanced knowledge on GA structural and functional relationships to ensure a consistent manufacturing of safe and effective products.

10 April 2019 in Journal of Immunology Research
Verified
Journal Article
Open access
AJAlexis P. Jiménez-Uribe
Alexis P. Jiménez-Uribe
HVHugo Valencia-Martínez
Hugo Valencia-Martínez
GCGregorio Carballo-Uicab
Gregorio Carballo-Uicab
Luis Vallejo-CastilloLuis Vallejo-Castillo
Luis Vallejo-Castillo
EMEmilio Medina-Rivero
Emilio Medina-Rivero
SPSonia Mayra Pérez-Tapia
Sonia Mayra Pérez-Tapia
Transferon® is a complex drug based on a mixture of low molecular weight peptides. This biotherapeutic is employed as a coadjuvant in clinical trials of several diseases, including viral infections and allergies. Given that macrophages play key roles in pathogen recognition, phagocytosis, processing, and antigen presentation, we evaluated the effect of Transferon® on phenotype and function of macrophage-like cells derived from THP-1 monocytes. We determined the surface expression of CD80 and CD86 by flow cytometry and IL-1β, TNF-α, and IL-6 levels by ELISA. Transferon® alone did not alter the steady state of PMA-differentiated macrophage-like THP-1 cells. On the contrary, simultaneous stimulation of cells with Transferon® and LPS elicited a significant increase in CD80 (P≤0.001) and CD86 (P≤0.001) expression, as well as in IL-6 production (P≤0.05) compared to the LPS control. CD80 expression and IL-6 production exhibited a positive correlation (r=0.6, P≤0.05) in cells exposed to Transferon® and LPS. Our results suggest that the administration of Transferon® induces the expression of costimulatory molecules and the secretion of cytokines in LPS-activated macrophages. Further studies are necessary to determine the implication of these findings in the therapeutic properties of Transferon®.

15 February 2019 in Journal of Food Science
Verified
Journal Article
Open access
PDF file
CLCarlos A. López‐Morales
Carlos A. López‐Morales
SVSaid Vázquez‐Leyva
Said Vázquez‐Leyva
Luis Vallejo-CastilloLuis Vallejo-Castillo
Luis Vallejo-Castillo
GCGregorio Carballo‐Uicab
Gregorio Carballo‐Uicab
LMLeslie Muñoz‐García
Leslie Muñoz‐García
EMEmilio Medina-Rivero
Emilio Medina-Rivero
Collagen hydrolysates are dietary supplements used for nutritional and medical purposes. They are complex mixtures of low‐molecular‐weight peptides obtained from the enzymatic hydrolysis of collagen, which provide intrinsic batch‐to‐batch heterogeneity. In consequence, the quality of these products, which is related to the reproducibility of their mass distribution pattern, should be addressed. Here, we propose an analytical approach to determine the peptide pattern as a quality attribute of Colagenart®, a product containing collagen hydrolysate. In addition, we evaluated the safety by measuring the viability of two cell lines exposed to the product. The consistency of peptide distribution was determined using Size Exclusion Chromatography (SEC), Mass Spectrometry coupled to a reversed phase UPLC system (MS‐RP‐UPLC), and Shaped‐pulse off‐resonance water‐presaturation proton nuclear magnetic resonance spectrometry [ 1 Hwater_presat NMR]. The mass distribution pattern determined by SEC was in a range from 1.35 to 17 kDa, and from 2 to 14 kDa by MS‐RP‐UPLC. [ 1 Hwater_presat NMR] showed the detailed spin‐systems of the collagen hydrolysates components by global assignment of backbone Hα and NH, as well as side‐chain proton resonances. Additionally, short‐range intraresidue connectivity pathways of identified spin‐regions were obtained by a 2D homonuclear shift correlation Shaped‐pulse solvent suppression COSY scheme. Safety analysis of Colagenart® was evaluated in CaCo‐2 and HepG2 cells at 2.5 and 25 μg/mL and no negative effects were observed. The results demonstrated batch‐to‐batch reproducibility, which evinces the utility of this approach to establish the consistency of the quality attributes of collagen hydrolysates. Practical Application: We propose state‐of‐the art analytical methodologies (SEC, MS, and NMR) to evaluate peptide profile and composition of collagen hydrolysates as quality attributes. These methodologies are suitable to be implemented for quality control purposes.

6 October 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAdriana I. Muñoz
Adriana I. Muñoz
Luis Vallejo-CastilloLuis Vallejo-Castillo
Luis Vallejo-Castillo
AFAna Fragozo
Ana Fragozo
SVSaid Vázquez-Leyva
Said Vázquez-Leyva
Lenin PavónLenin Pavón
Lenin Pavón
SPSonia Mayra Pérez-Tapia
Sonia Mayra Pérez-Tapia
Canine parvovirus type II (CPV-2) infection induces canine parvoviral enteritis (CPE), which in turn promotes sepsis and systemic inflammatory response syndrome (SIRS). Mortality in this disease is usually registered within 48–72 h post-hospitalization, the critical period of the illness. It has been recently described that the use of an immunomodulator, whose major component is monomeric ubiquitin (mUb) without the last two glycine residues (Ub∆GG), in pediatric human patients with sepsis augments survival. It is known that CXCR4 is the cell receptor of extracellular ubiquitin in humans. This work aimed to explore the effect of one immunomodulator (human Dialyzable Leukocyte Extract-hDLE) as a therapeutic auxiliary in puppies with sepsis and SIRS induced by CPE. We studied two groups of puppies with CPV-2 infection confirmed by polymerase chain reaction. The first group received conventional treatment (CT) and vehicle (V), while the second group received CT plus the immunomodulator (I). We assessed both groups' survival, clinical condition, number of erythrocytes, neutrophils, and lymphocytes during the hospitalization period. In addition, hematocrit, hemoglobin, plasma proteins and cortisol values, as well as norepinephrine/epinephrine and serotonin concentration were determined. Puppies treated with CT + I showed 81% survival, mild clinical signs, and a significant decrease in circulating neutrophils and lymphocytes in the critical period of the treatment. In contrast, the CT + V group presented a survival of 42%, severe clinical status, and no improvement of the parameters evaluated in the critical period of the disease. We determined in silico that human Ub∆GG can bind to dog CXCR4. In conclusion, the administration of a human immunomodulator (0.5 mg/day × 5 days) to puppies with CPE under six months of age reduces the severity of clinical signs, increases survival, and modulates inflammatory cell parameters. Further studies are necessary to take full advantage of these clinical findings, which might be mediated by the human Ub∆GG to canine CXCR4 interaction.

29 March 2023 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
LVLuis Vázquez-Flores
Luis Vázquez-Flores
JCJessica Castañeda-Casimiro
Jessica Castañeda-Casimiro
Luis Vallejo-CastilloLuis Vallejo-Castillo
Luis Vallejo-Castillo
VÁVioleta D Álvarez-Jiménez
Violeta D Álvarez-Jiménez
EPEliud S Peregrino
Eliud S Peregrino
IWIsabel Wong-Baeza
Isabel Wong-Baeza
Tuberculosis remains one of the leading public health problems in the world. The mechanisms that lead to the activation of the immune response against Mycobacterium tuberculosis (Mtb) have been extensively studied, with a focus on the role of cytokines as the main signals for immune cell communication. However, less is known about the role of other signals, such as extracellular vesicles (EVs), in the communication between immune cells, particularly during the activation of the adaptive immune response. In this study, we determined that EVs released by human neutrophils infected with Mtb (EV-Mtb) contained several host proteins that are ectosome markers. In addition, we demonstrated that EV-Mtb released after only 30 min of infection carried mycobacterial antigens and pathogen-associated molecular patterns, and we identified 15 mycobacterial proteins that were consistently found in high concentrations in EV-Mtb; these proteins contain epitopes for CD4 T cell activation. We found that EV-Mtb increased the expression of the co-stimulatory molecule CD80 and of the co-inhibitory molecule PD-L1 on immature monocyte-derived dendritic cells. We also found that immature and mature dendritic cells treated with EV-Mtb were able to induce IFN-γ production by autologous Mtb antigen-specific CD4 T cells, indicating that these EVs acted as antigen carriers and transferred mycobacterial proteins to the antigen-presenting cells. Our results provide evidence that EV-Mtb participate in the activation of the adaptive immune response against Mtb.

20 July 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
EMEmilio Medina-Rivero
Emilio Medina-Rivero
Luis Vallejo-CastilloLuis Vallejo-Castillo
Luis Vallejo-Castillo
SVSaid Vázquez-Leyva
Said Vázquez-Leyva
Gilberto Pérez--SánchezGilberto Pérez--Sánchez
Gilberto Pérez--Sánchez
LFLiliana Favari
Liliana Favari
SPSonia Mayra Pérez-Tapia
Sonia Mayra Pérez-Tapia
Transferon, a biotherapeutic agent that has been used for the past 2 decades for diseases with an inflammatory component, has been approved by regulatory authorities in Mexico (COFEPRIS) for the treatment of patients with herpes infection. The active pharmaceutical ingredient (API) of Transferon is based on polydispersion of peptides that have been extracted from lysed human leukocytes by a dialysis process and a subsequent ultrafiltration step to select molecules below 10 kDa. To physicochemically characterize the drug product, we developed chromatographic methods and an SDS-PAGE approach to analyze the composition and the overall variability of Transferon. Reversed-phase chromatographic profiles of peptide populations demonstrated batch-to-batch consistency from 10 representative batches that harbored 4 primary peaks with a relative standard deviation (RSD) of less than 7%. Aminogram profiles exhibited 17 proteinogenic amino acids and showed that glycine was the most abundant amino acid, with a relative content of approximately 18%. Further, based on their electrophoretic migration, the peptide populations exhibited a molecular mass of about 10 kDa. Finally, we determined the Transferon fingerprint using a mass spectrometry tool. Because each batch was produced from independent pooled buffy coat samples from healthy donors, supplied by a local blood bank, our results support the consistency of the production of Transferon and reveal its peptide identity with regard to its physicochemical attributes.